ArticleFrontiers in bioengineering and biotechnology2026
A Trojan horse nanoplatform overcoming delivery barriers for targeted gene immunotherapy of colorectal cancer.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Programmed cell death ligand 1 (PD-L1) antibody has been shown to hold tremendous promise in curing metastatic colorectal cancer (CRC). However, the delivery efficacy of the targeted biologics limits this immunotherapy in a subset of CRC. Here we report a novel biomimetic 'Trojan horse' nano-delivery system for targeted gene-immunotherapy of colorectal cancer. The system comprises a core of gold nanoparticles and cationic liposomes encapsulating CRISPR/Cas9-sgSOX9, camouflaged with homologous CRC cell membranes for immune evasion and tumor tropism, and functionalized with PD-L1 antibodies to enhance tumor recognition and relieve immune suppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.